Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats

Drug Metabolism and Disposition

Volumn 39, Issue 1, 2011, Pages 8-14

  Sugimoto, Hiroshi ^a   Hirabayashi, Hideki ^a   Kimura, Yoshiaki ^a   Furuta, Atsutoshi ^a   Amano, Nobuyuki ^a   Moriwaki, Toshiya ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DIGOXIN; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; QUINIDINE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG TRANSPORT; MALE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; STEADY STATE;

ACRIDINES; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CYCLOSPORINE; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; LLC-PK1 CELLS; MALE; P-GLYCOPROTEIN; RATS; SWINE; TETRAHYDROISOQUINOLINES; UP-REGULATION;

RATTUS;

EID: 78650747680     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035774     Document Type: Article

References (31)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668.
2. Angelin B, Arvidsson A, Dahlqvist R, Hedman A, and Schenck-Gustafsson K (1987) Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17:262-265.
3. Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, and Reid JG (1987) The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol 33:531-534.
4. Brunton L, Lazo J, and Parker K (2005) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed, McGraw-Hill Publishers, New York.
5. Cutler L, Howes C, Deeks NJ, Buck TL, and Jeffrey P (2006) Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J Pharm Sci 95:1944-1953.
6. Dorian P, Strauss M, Cardella C, David T, East S, and Ogilvie R (1988) Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med 11:108-112.
7. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM (2008) In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275.
8. Gao B, Stieger B, Noé B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
9. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, and Schenck-Gustafsson K (1991) Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49:256-262.
11. Hirabayashi H, Sugimoto H, Amano N, and Moriwaki T (2010) Impact of P-gp inhibition on the drug transport across the blood brain barrier (I) development of a high-sensitive and accurate analytical LC/MS/MS method for digoxin, a typical P-glycoprotein substrate, in rat brain. 25th Japanese Society for the Study of Xenobiotics Annual Meeting; 2010 Oct 7-9; Tokyo, Japan. The Japanese Society for the Study of Xenobiotics, Tokyo, Japan.
12. Hsiao P, Bui T, Ho RJ, and Unadkat JD (2008) In vitro-to-in vivo prediction of P-glycoproteinbased drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 36:481-484.
13. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, and Unadkat JD (2006) Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317:704-710.
14. Jalava KM, Olkkola KT, and Neuvonen PJ (1997a) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61:410-415.
15. Jalava KM, Partanen J, and Neuvonen PJ (1997b) Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 19:609-613.
16. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276.
17. Keogh JP and Kunta JR (2006) Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27:543-554.
18. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Østergaard M, Autrup H, and Andersen V (2007) Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 67:123-134.
19. McTavish D and Sorkin EM (1989) Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19-76. (Pubitemid 19203576)
20. Noé B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
21. Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, and Sugiyama Y (2010) Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168-176.
22. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
23. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
24. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
25. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
26. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
27. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, and Asahi S (2006) Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23:1460-1472.
28. Tsuji A (2006) Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. J Infect Chemother 12:241-250.
29. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, and Yamashita J (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51:1427-1437.
30. Ueda CT, Williamson BJ, and Dzindzio BS (1976) Absolute quinidine bioavailability. Clin Pharmacol Ther 20:260-265.
31. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885.